Introduction: Adenomas with neuroendocrine differentiation are defined as neuroendocrine neoplasms, and they are rarely found in the head and neck. Objective: To describe two cases of a middle ear adenoma with neuroendocrine differentiation, with a literature review. Case Report: Patient 1 was a 41-year-old woman who presented with a 3-year history of left aural fullness associated with ipsilateral "hammer beating" tinnitus. Patient 2 was a 41-year-old male who presented with unilateral conductive hearing loss. Conclusion: Adenoma with neuroendocrine differentiation of the middle ear is a rare entity, but it should be considered in patients with tinnitus, aural fullness, and a retrotympanic mass and remembered as a diferential diagnosis of tympanic paraganglioma.
INTRODUCTION
Neuroendocrine cells are generally present in the respiratory epithelium as well as in the bronchial and intestinal mucosa. A few of these cells are also associated with epithelial structures found throughout the body, including the head and neck. Adenomas with neuroendocrine differentiation are defined as neuroendocrine neoplasms, and they are rarely found in the head and neck. When they occur in this region, they are more commonly found in the larynx (1) . They usually grow in the lungs or gastrointestinal tract (1, 2) .
CASE REPORTS
Patient 1 was a 41-year-old woman who presented with a 3-year history of left aural fullness associated with ipsilateral "hammer beating" tinnitus. Over the following 8 months, the patient developed left-side otalgia and was treated with systemic antibiotics but without any improvement.
The patient consulted a colleague who raised the possibility of a tympanic paraganglioma. Computed tomography (CT) of the temporal bones revealed a material with a soft tissue density that diffusely obliterated the left mastoid cells, but with no signs of ossicular chain erosion ( Figure 1) . Angiography of the temporal bone showed a lobulated solid lesion with defined limits and contrast uptake within the left middle ear and the epitympanic recess.
The patient consulted our institution when her symptoms persisted. She had no complaints of hearing loss or otorrhea. On examination, the patient was found to be in good general condition and without neurological deficits. Otoscopy of the right ear was normal, but a retrotympanic, non-pulsatile mass was detected in the left ear ( Figure 2 ). Figure 3 demonstrates her puretone audiometry, with a 10dB-gap in the left ear. She subsequently underwent a left radical mastoidectomy with total resection of the lesion. Intraoperatively, the tumor had a fibrous aspect and filled the antrum and the entire tympanic cavity, involving the ossicular chain. The histopathological study was compatible with middle ear adenoma with neuroendocrine differentiation.
Patient 2 was a 41-year-old man who presented with unilateral conductive hearing loss. CT scan showed a middle ear mass in the promontory mimicking a tympanic paraganglioma ( Figure 4 ). Magnetic ressonance imaging (MRI) of the temporal bones revealed a small mass in the left tympanic cavity with isosignal in T1 and post-contrast enhancement on T2 sequences( Figure 5 ). The patient underwent surgical intervention through a supra-meatal then, approximately 40 cases have been described in the English literature (1).
The incidence of this tumor in the middle ear is difficult to establish since it may be confused with adenomatous tumors, ceruminomas, and even with other tumors, such as paragangliomas (1).
Clinically, it presents with conductive hearing loss and ear fullness. Less frequently, patients may complain of tinnitus, headache, and even facial paralysis (5) . In most cases, otoscopy demonstrates an intact tympanic membrane with a retrotympanic mass, as occurred in this case. Carcinoid syndrome (flushing, sweating, and diarrhea) is not found in these patients because of the small production of vasoactive peptides. Distant metastases are rare events (1, 5) . Imaging studies consistently show a locally infiltrative mass and may show invasion of the ossicles (4).
Middle ear adenoma with neuroendocrine differentiation can be distinguished from adenomatous tumors (adenomas, adenocarcinomas, and adenoid cystic carcinomas), ceruminomas, and paragangliomas by their light microscopic appearance, argyrophilic granules, and ultrastructural evidence of neurosecretory granules, as well as by immunohistochemical detection of various neuroendocrine markers. These include neuron-specific enolase, chromogranin, synaptophysin, serotonin, glucagon, insulin, gastrin, vasoactive intestinal polypeptide, pancreatic polypeptide, and calcitonin (4).
DISCUSSION
We reported two cases of middle ear adenoma with neuroendocrine differentiation wich presented with unspecific clinical manifestations. In both cases, the radiological features were very similar to tympanic paraganglioma, wich is the most frequent tumoral lesion of the middle ear. The final diagnosis was provided by histological and immunohistochemical analysis of the tumor.
The recommended treatment is complete surgical excision of the lesion and the technique used is determined by the size and involvement of adjacent structures (1). Radiotherapy is not indicated since the tumor has poor radiosensitivity (1). The prognosis is good, however, a rigorous postoperative follow-up is indicated for all patients (3).
Our patients underwent surgical treatment and clinical follow-up in conjunction with the Oncology department. One of the patients (patient 1) had imaging studies performed 18 months after surgery, wich confirmed that there were no signs of disease recurrence.
FINAL COMMENTS
Middle ear adenoma with neuroendocrine differentiation is a rare entity, but it should be considered as a possible diagnosis in patients with hearing loss, tinnitus, aural fullness, and a retrotympanic mass.
